CAJ | 학술논문

目的探讨足叶乙甙联合氨甲喋呤治疗骨肉瘤的理论和实验依据，为临床设计新的化疗方案奠定基础。方法应用MTT比色法测定足叶乙甙及氨甲喋呤对OS-732和R-OS-732细胞活性的影响，比较两种化疗药物对骨肉瘤细胞的敏感性。应用免疫组化检测TOPO-Ⅱ在骨肉瘤中的表达。临床在采用日本国立癌中心化疗方案的基础上联合应用足叶乙甙治疗骨肉瘤5例，随访2～5年。结果氨甲喋呤的IC50值，OS-732 为596.85mg/ml±0.85;R-OS-732为5170.965mg/ml±1.45(OS-732与R-OS-732相比差异显著P<0.05)。而足叶乙甙的IC50值，OS-732O 1.25ug/ml±0.04；R-OS-732为1.45ug/ml ±0.03(OS-732与R-OS-732相比差异不显著P>0.05)。TOPO-Ⅱ在骨肉瘤术前化疗组明显高于术前无化疗组，分别为60%(3/5)和40%(2/5)。经足叶乙甙联合氨甲喋呤治疗的5例骨肉瘤均存活，最长存活5年，其他仍在随访中。结论足叶乙甙联合氨甲喋呤治疗骨肉瘤是有效的，尤其是对于复发病例效果会更好。
목적탐토족협을대연합안갑첩령치료골육류적이론화실험의거，위림상설계신적화료방안전정기출。방법응용MTT비색법측정족협을대급안갑첩령대OS-732화R-OS-732세포활성적영향，비교량충화료약물대골육류세포적민감성。응용면역조화검측TOPO-Ⅱ재골육류중적표체。림상재채용일본국립암중심화료방안적기출상연합응용족협을대치료골육류5례，수방2～5년。결과안갑첩령적IC50치，OS-732 위596.85mg/ml±0.85;R-OS-732위5170.965mg/ml±1.45(OS-732여R-OS-732상비차이현저P<0.05)。이족협을대적IC50치，OS-732O 1.25ug/ml±0.04；R-OS-732위1.45ug/ml ±0.03(OS-732여R-OS-732상비차이불현저P>0.05)。TOPO-Ⅱ재골육류술전화료조명현고우술전무화료조，분별위60%(3/5)화40%(2/5)。경족협을대연합안갑첩령치료적5례골육류균존활，최장존활5년，기타잉재수방중。결론족협을대연합안갑첩령치료골육류시유효적，우기시대우복발병례효과회경호。
Objective　To study theoretical and experimental b asis for the usage of VP-16 and MTX in the treatment of osteosarcoma.Me thods　The effect of VP-16 and MTX on the cytoactivity of OS-732 cells and R-OS-732 cells was detected by MTT assay.Expression of TOPO-Ⅱ in 13 cas es of osteosarcoma was detected by immunohistochemical assay.5 cases of osteosar coma were treated with the VP-16 on the basis of Japan chemotherapeutical regim en.Results　IC50 value of MTX in OS-732 and R-OS-732 cells wa s 596.85±0.85mg/ml and 5170±965 1.45mg/ml respectively.While for VP-16,It wa s 1.25±0.04 for OS-732 cells,1.45-0.03 for R-OS-732 cells.The positive rate of TOPO-Ⅱ expression in the group with pre-operative chemotherapy was higher than that without pre-operative themotherapy.All 5 cases of os teosarcoma survived up to now and the longest survivor is over 5 years.C onclusions　VP-16 is very effective in the treatment of osteosarcoma.